By Associate Professor Megan Amanda Crumbaker

Journal articles

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104

Goode D; Keerthikumar S; Gupta S; Joshua AM; Emmett L; Crumbaker M; Singer T; Lam E; Fernandez L; Jimenez E; Zhang D; Lin Y; Wenstrup RJ; PASAM A; Hicks R; Kong G; Hamid A; Sandhu SK, 2023, '1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', Annals of Oncology, 34, pp. s988 - s989, http://dx.doi.org/10.1016/j.annonc.2023.09.2773

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JCH; Pattison DA; Tan H; Kirkwood ID; Sandhu SK; Nguyen A; Gedye C; Rutherford N; Hofman M; Martin A; Stockler MR; Davis ID, 2023, 'LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)', Annals of Oncology, 34, pp. s1325, http://dx.doi.org/10.1016/j.annonc.2023.10.086

Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG, 2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20, http://dx.doi.org/10.1186/s12916-022-02298-0

Chen S; Petricca J; Ye W; Guan J; Zeng Y; Cheng N; Gong L; Shen SY; Hua JT; Crumbaker M; Fraser M; Liu S; Bratman SV; van der Kwast T; Pugh T; Joshua AM; De Carvalho DD; Chi KN; Awadalla P; Ji G; Feng F; Wyatt AW; He HH, 2022, 'The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-34012-2

Joshua AM; Armstrong A; Crumbaker M; Scher HI; de Bono J; Tombal B; Hussain M; Sternberg CN; Gillessen S; Carles J; Fizazi K; Lin P; Duggan W; Sugg J; Russell D; Beer TM, 2022, 'Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER', European Journal of Cancer, 170, pp. 285 - 295, http://dx.doi.org/10.1016/j.ejca.2022.04.005

Chan DL; Pavlakis N; Crumbaker M; Lawrence B; Barber C; Price TJ; Michael M; Oberg K, 2022, 'Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series', Asia Pacific Journal of Clinical Oncology, 18, pp. 209 - 216, http://dx.doi.org/10.1111/ajco.13577

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552

Conduit C; Mak B; Qu W; Lulio JD; Burder R; Bressel M; Cusick T; Dhillon HM; Lourenço RDA; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Allen R; Davis ID; Clark SJ; Horvath LG; Mahon KL, 2022, 'GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)', Therapeutic Advances in Medical Oncology, 14, http://dx.doi.org/10.1177/17588359221092486

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden AJ; Brooks A; Patel MI; Lau H; Woo H; Bariol S; Gurney H, 2022, 'Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center', Asia Pacific Journal of Clinical Oncology, 18, pp. e23 - e31, http://dx.doi.org/10.1111/ajco.13548

Joshua AM; Gurney H; Dhillon HM; Crumbaker M, 2022, 'Patient Preference or Indifference: Learning from the CABADOC Study', European Urology, 81, pp. 241 - 242, http://dx.doi.org/10.1016/j.eururo.2021.11.005

Nguyen LT; Lo CS; Fyrsta M; Nie J; Yam JY; Yen PH; Le MX; Hersey K; Kenk M; Crumbaker M; Fleshner N; Kulkarni G; Hamilton R; Jewett M; Finelli A; Evans A; Sweet J; Ohashi PS; Joshua AM, 2022, 'Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue', Prostate Cancer, 2022, http://dx.doi.org/10.1155/2022/6499344

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European Urology Oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002

Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID, 2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491

Lin HM; Mak B; Yeung N; Huynh K; Meikle TG; Mellett NA; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Crumbaker M; Stricker PD; Du P; Yu J; Jia S; Scheinberg T; Fitzpatrick M; Bonnitcha P; Sullivan DR; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', Ebiomedicine, 72, http://dx.doi.org/10.1016/j.ebiom.2021.103625

Lin HM; Yeung N; Hastings JF; Croucher DR; Huynh K; Meikle TG; Mellett NA; Kwan EM; Davis ID; Tran B; Mahon KL; Zhang A; Stockler MR; Briscoe K; Marx G; Bastick P; Crumbaker ML; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13, http://dx.doi.org/10.3390/cancers13194964

Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LJK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA, 2021, 'Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer', Translational Andrology and Urology, 10, http://dx.doi.org/10.21037/tau-20-1444

Bhatnagar A; McKay MJ; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP, 2020, 'Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma', Journal of Mass Spectrometry, 55, http://dx.doi.org/10.1002/jms.4584

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177 Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557

Crumbaker M; Chan EKF; Gong T; Corcoran N; Jaratlerdsiri W; Lyons RJ; Haynes AM; Kulidjian AA; Kalsbeek AMF; Petersen DC; Stricker PD; Jamieson CAM; Croucher PI; Hovens CM; Joshua AM; Hayes VM, 2020, 'The impact of whole genome data on therapeutic decision‐making in metastatic prostate cancer: A retrospective analysis', Cancers, 12, http://dx.doi.org/10.3390/cancers12051178

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120

Quah GT; Espinoza D; Arasaratnam M; Crumbaker M; Balakrishnar B; Brooks A; Lau H; Patel M; Bariol S; Gurney H, 2020, '212P Stage I non-seminoma testicular cancer: Adjuvant management and outcomes', Annals of Oncology, 31, pp. S1323 - S1323, http://dx.doi.org/10.1016/j.annonc.2020.10.223

Quah GT; Espinoza D; Crumbaker M; Balakrishnar B; Arasaratnam M; Bariol S; Brooks A; Lau H; Patel M; Gurney H, 2020, '213P Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance', Annals of Oncology, 31, pp. S1323 - S1323, http://dx.doi.org/10.1016/j.annonc.2020.10.224

Bhatnagar A; McKay MJ; Thaysen-Andersen M; Arasaratnam M; Crumbaker M; Gurney H; Molloy MP, 2019, 'Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients', Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 1126-1127, http://dx.doi.org/10.1016/j.jchromb.2019.121741

Crumbaker M; Wong J; Joshua AM; Spigelman AD, 2019, 'Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center', Asia Pacific Journal of Clinical Oncology, 15, pp. 257 - 261, http://dx.doi.org/10.1111/ajco.13148

Arasaratnam M; Crumbaker M; Bhatnagar A; McKay MJ; Molloy MP; Gurney H, 2019, 'Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer', Cancer Chemotherapy and Pharmacology, 84, pp. 139 - 146, http://dx.doi.org/10.1007/s00280-019-03862-x

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of 177 Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to 177lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

Bhatnagar A; McKay MJ; Crumbaker M; Ahire K; Karuso P; Gurney H; Molloy MP, 2018, 'Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry', Journal of Pharmaceutical and Biomedical Analysis, 154, pp. 66 - 74, http://dx.doi.org/10.1016/j.jpba.2018.03.012

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden A; Brooks A; Patel M; Gurney H, 2018, 'Patterns of care and outcome of germ cell tumours (GCT) in an Australian high-volume centre.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e16534

Crumbaker M; Savdie R; Joshua AM, 2018, 'Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer', European Urology, 73, pp. 736 - 737, http://dx.doi.org/10.1016/j.eururo.2017.11.005

Crumbaker M; Guminski A; Gurney H; Sabanathan D; Wong S; Pavlakis N, 2018, 'Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia', Asia Pacific Journal of Clinical Oncology, 14, pp. e45 - e49, http://dx.doi.org/10.1111/ajco.12686

Crumbaker M; Gurney H, 2017, 'Dose considerations for anti-cancer drugs in metastatic prostate cancer', Prostate, 77, pp. 1199 - 1204, http://dx.doi.org/10.1002/pros.23378

Crumbaker M; Khoja L; Joshua AM, 2017, 'AR signaling and the PI3K pathway in prostate cancer', Cancers, 9, pp. 34, http://dx.doi.org/10.3390/cancers9040034

Mersiades A; Crumbaker M; Gao B; Nagrial A; Hui R, 2017, 'P3.02c-033 Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer', Journal of Thoracic Oncology, 12, pp. S1293 - S1293, http://dx.doi.org/10.1016/j.jtho.2016.11.1828

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, 27, http://dx.doi.org/10.1093/annonc/mdw594.035

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, 27, pp. ix151 - ix151, http://dx.doi.org/10.1016/s0923-7534(21)00629-3

Chan D; McLachlan JM; Crumbaker M; Marx GM, 2015, 'Pretreatment neutrophil/lymphocyte ratio (NLR) prior to steroids as a prognostic factor in metastatic castrate refractory prostate cancer (mCRPC) patients treated with taxanes.', JOURNAL OF CLINICAL ONCOLOGY, 33, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.273

McLachlan JM; Chan DL; Crumbaker MA; Marx GM, 2015, 'Neutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer', Cancer Treatment Communications, 4, pp. 81 - 85, http://dx.doi.org/10.1016/j.ctrc.2015.06.001

Conference Papers

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Agrawal S; Poole A; Eu P; Crumbaker M; Chan L; Nguyen A, 2023, 'Patient outcomes following a response biomarker guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate resistant prostate cancer (Re-SPECT)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, INDIA, Jodhpur, presented at 55th Annual Conference of the Society-of-Nuclear-Medicine (SNMICON), INDIA, Jodhpur, 16 November 2023 - 19 November 2023

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Conduit C; Mak B; Qu W; Yeung T; Bressel M; Cusick T; Dhillon HM; Lourenco RDA; Underhill C; Torres J; Crumbaker M; Honeyball F; Linton A; Sewak S; Chau NMH; Allen R; Davis ID; Clark SJ; Horvath L; Mahon KL, 2023, 'GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Kumar AR; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020

Crumbaker M; Joshua AM; Epstein R; Emmett L, 2018, 'A phase I study of ¹⁷⁷Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.TPS5088

Arasaratnam M; Balakrishnar B; Crumbaker M; Turner S; Hayden AJ; Brooks A; Patel MI; Gurney H, 2018, 'Patterns of Care and Outcome of Germ Cell Tumours (GCT) in an Australian High-Volume Centre', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 28 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000437670700015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Itchins M; Sinn K; Chan D; Crumbaker M; Gill A; Clarke S; Pavlakis N, 2015, 'ALK TRANSLOCATED NON-SMALL CELL LUNG CANCER: EXPERIENCE FROM AN AUSTRALIAN METROPOLITAN TERTIARY REFERRAL CENTRE', in Asia-Pacific Journal of Clinical Oncology, WILEY-BLACKWELL, pp. 174 - 175, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000364320800315&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Presentations

Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L, 2024, 'Comparison of Post-Therapy 4 and 24-hour 177Lu-PSMA SPECT/CT and Pre-Therapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castrate-Resistant Prostate Cancer', presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CANADA, Toronto, 08 June 2024 - 11 June 2024, https://jnm.snmjournals.org/content/65/supplement_2/242460

Back to profile page